Neoprobe 3rd Quarter and Business Update Conference Call Invitation

Conference Call Scheduled for 11:00 AM ET, Tuesday, November 3rd DUBLIN, Ohio–(Business Wire)

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced it would report its financial results for the third quarter of 2009 on Monday, November 2, 2009 after the close of the financial markets. The Company has scheduled a conference call with the investment community to discuss the financial results for the following morning, Tuesday, November 3, 2009 at 11:00 AM ET.

During the conference call, Neoprobe`s President and CEO, David Bupp, and Vice President and CFO, Brent Larson, will provide a business update and discuss the Company`s results for the third quarter and first three quarters of 2009.

The conference call can be accessed as follows:

Conference Call Information

Date: Nov. 3, 2009 Available until: Nov. 10, 2009
Time: 11:00 AM ET Toll-free (U.S.) Dial in #: 877-660-6853

International Dial in # : 201-612-7415
Toll-free (U.S.) Dial in # : 877-407-8033 Replay Passcodes:
International Dial in # : 201-689-8033 Account #: 286
Conference ID #: 336400

About Neoprobe

Neoprobe is a biomedical company focused on enhancing patient care and improving
patient outcome by meeting the critical intraoperative diagnostic information
needs of physicians and therapeutic treatment needs of patients. Neoprobe
currently markets the neoprobe® GDS line of gamma detection systems that are
widely used by cancer surgeons. In addition, Neoprobe holds significant
interests in the development of related biomedical systems and
radiopharmaceutical agents including Lymphoseek® and RIGScan® CR. Neoprobe`s
subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific
cellular therapy technology platform called ACT. Neoprobe`s strategy is to
deliver superior growth and shareholder return by maximizing its strong position
in gamma detection technologies and diversifying into new, synergistic
biomedical markets through continued investment and selective acquisitions.